Validation of Highly Sensitive TargetSelector™ ctDNA Assays for EGFR, BRAF, and KRAS Mutations

Shan-Fu Wu, PhD; Timothy T. Lu, PhD; Anh Pham; Jeffrey Chen; Tony Daher; Errin Samuelsz; Manisha Patel; Veena M. Singh, MD; Lyle J. Arnold, PhD; Jason C. Poole, PhD

Biocept, San Diego, CA, USA

Background

Accurate detection of actionable mutations in patients with cancer is vital for targeted therapy. Compared to tissue biopsy, ‘liquid biopsy’ offers a non-invasive and more systemic approach to identify tumor mutations by assessing circulating tumor DNA (ctDNA) released from tumor cells into peripheral blood. We have developed TargetSelector™ Real-Time PCR based assays to detect low frequency mutant alleles in ctDNA. The TargetSelector™ assays use a patented blocking approach to suppress amplification of excess WT DNA released from normal cells, while allowing specific amplification of mutations. Here we focus on five important targets: EGFR Del19, L858, and T790, BRAF V600, and KRAS (G12/G13), which are relevant to lung cancer, melanoma, and colorectal cancer.

TargetSelector™ ctDNA Assay Workflow & Diagram

Methods

The TargetSelector™ ctDNA assays apply a specific blocker to cover variants on a short stretch of target DNA (up to 15 bp for nucleotide variants). For example, one KRAS exon 2 blocker covers all variants on both G12 and G13 codon positions. DNA from cancer cell lines carrying the specific target mutations were used for analytical validation of the TargetSelector™ ctDNA assays incorporating the QuantStudio 5 (Q5) Real-Time PCR instrument (Thermo Fisher). Sanger or NGS DNA sequencing was subsequently performed to confirm the mutations. Analytical validation was conducted by 3 independent operators using 5 instruments across 5 days in Biocept’s CLIA-certified and CAP-accredited laboratory. For ctDNA testing, whole blood samples were collected in CEE-Sure™ Blood Collection tubes and DNA extraction from plasma was performed using the QIAsymphony (QIAGEN).

Results

In total, we tested 3086 samples for EGFR, BRAF, and KRAS TargetSelector™ ctDNA assays for analytical validation, with EGFR WT assay as the background reference. The inter-assay and intra-assay analyses showed CV<5%, suggesting a consistent performance among operational variables. Each Biocept’s TargetSelector™ ctDNA assay showed >99% analytical sensitivity and >99% analytical specificity. Samples tested from 20 healthy donors (100 tests in total) showed clinical specificity >99%.

Analytical Validation of TargetSelector™ Assays

<table>
<thead>
<tr>
<th>cDNA Assay</th>
<th>Analytical Sensitivity (FP/TP)</th>
<th>Analytical Specificity (FP/TN)</th>
<th>LOD</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGFR Del19</td>
<td>&gt;99% (0/11) ≥99% (1/11)</td>
<td>0.02%</td>
<td></td>
</tr>
<tr>
<td>EGFR L858</td>
<td>&gt;99% (0/116) ≥99% (1/116)</td>
<td>0.02%</td>
<td></td>
</tr>
<tr>
<td>EGFR T790</td>
<td>&gt;99% (0/138) ≥99% (1/138)</td>
<td>0.02%</td>
<td></td>
</tr>
<tr>
<td>BRAF V600</td>
<td>&gt;99% (1/135) ≥99% (2/135)</td>
<td>0.02%</td>
<td></td>
</tr>
<tr>
<td>KRAS exon 2</td>
<td>&gt;99% (0/336) ≥99% (1/336)</td>
<td>0.02%</td>
<td></td>
</tr>
</tbody>
</table>

Table 1: Each Biocept’s TargetSelector™ ctDNA assay was analytically validated and showed >99% analytical sensitivity and >99% analytical specificity. Limit of detection (LOD) for each assay was tested in the presence of 14,000 WT copies, and showed sensitivity at 0.02% WT DNA or better. FN, false negative; TP, true positive; FP, false positive; TN, true negative.

Single Copy Sensitivity of TargetSelector™ Assays

Figure 2: Detection sensitivity of each ctDNA assay was determined through a serial dilution of mutant copies in the absence of WT copies. A. Histograms for the frequency of copy number detection in >99% (0/138) >99% (0/112) 0.01% . B. Box plots show the theoretical profiles based on a Poisson distribution, with corresponding sample numbers (N) for each standard. The actual data is within the theoretical model. C. Based on the experimental dataset, we used the estimating method in statistics, maximum likelihood estimation, to estimate the mutant copy number at each standard level. Digital droplet PCR was used as an orthogonal method to confirm the level of the serial dilution.

Clinical Experience of TargetSelector™ ctDNA Assays using the QuantStudio 5

Table 3: Whole blood samples from patients with cancer were collected in Biocept’s CEE-Sure™ Blood Collection tubes. Plasma and ctDNA were isolated, and TargetSelector™ ctDNA assays were then run in Biocept’s CLIA-certified and CAP-accredited laboratory. All samples shown here were tested using the Q5. A. Samples comprise various cancer types including lung, breast, colorectal, and melanoma cancer. B. NSCLC. (non-small cell lung cancer) samples are shown. Expected frequencies are referenced from “mycancergenome.com”. Samples for EGFR TT90M include both untreated and treated patients.

Conclusions

• Each Biocept’s TargetSelector™ ctDNA assay shows >99% analytical sensitivity and >99% analytical specificity.
• TargetSelector™ ctDNA assays show single mutant copy detection based on experimental data compared to theoretical estimates, with sensitivity at 0.02% WT DNA or better in a background of WT DNA.
• Biocept’s ctDNA assays detected no false positives from 20 healthy donors, and showed >99% clinical specificity.
• Implementation of the QuantStudio 5 platform into Biocept’s TargetSelector™ ctDNA assays translated into high clinical sensitivity and fast turnaround time for patients in Biocept’s CLIA-certified and CAP-accredited laboratory.